Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.39 |
| ▸ | BRD4 | O60885 | 8/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1933955 | 0.87 | MTNR1A (0.38) | BRD4DYRK1ADGAT1KLKB1GSK3B | |
| SCHEMBL16261058 | 0.82 | AURKA (0.38) | NAMPTDGAT1GSK3BNPC1MAPT | |
| SCHEMBL1536772 | 0.80 | MTNR1A (0.39) | BRD4DYRK1ADGAT1KLKB1GSK3B | |
| SCHEMBL2321156 | 0.77 | LCK (0.38) | GSK3B | |
| SCHEMBL1933848 | 0.75 | GSK3B (0.38) | NAMPTDYRK1ADGAT1KLKB1GSK3B | |
| SCHEMBL4354849 | 0.73 | MTNR1A (0.39) | DGAT1GSK3B | |
| SCHEMBL1536998 | 0.72 | LCK (0.40) | GSK3B | |
| SCHEMBL2359998 | 0.71 | DGAT1 (0.39) | NAMPTBRD4DYRK1ADGAT1KLKB1 | |
| SCHEMBL2319933 | 0.70 | GSK3B (0.42) | DYRK1ADGAT1GSK3B | |
| SCHEMBL1536841 | 0.69 | MTNR1A (0.42) | GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140349970-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2014-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349970-A1 | NOVEL TRICYCLIC COMPOUNDS | CCNI, IL2, IL4I1 | NAMPT 2833/4885BRD4 1047/4885DYRK1A 4131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.